Claims
- 1. A compound having the formula ##STR20## or a pharmaceutically acceptable salt thereof wherein R and R.sub.1 are each hydrogen or alkyl, R is hydrogen and R.sub.1 is alkenyl, alkynyl, aryl, heteroaryl or cycloalkyl, or R and R.sub.1 together with the carbon atom to which they are attached are cycloalkyl;
- R.sub.2 and R.sub.3 are each independently hydrogen, alkyl, cycloalkyl, or arylalkyl or R.sub.2 and R.sub.3 together with the nitrogen atom to which they are attached are pyrrolidinyl, piperidinyl, or morpholinyl;
- R.sub.4 and R.sub.5 are each independently hydrogen, halogen, alkyl, alkoxy, aryloxy, arylalkoxy, arylalkyl, hydroxy, alkanoyloxy, ##STR21## difluoromethoxy, trifluoromethyl, --NX.sub.3 X.sub.4, --SO.sub.m alkyl, or --SO.sub.m aryl;
- n is 2 or 3;
- m is 0, 1 or 2;
- X.sub.1 and X.sub.2 are each independently hydrogen, alkyl, aryl or heteroaryl, or X.sub.1 and X.sub.2 together with the nitrogen atom to which they are attached are a nitrogen containing heteroaryl;
- X.sub.3 and X.sub.4 are each independently hydrogen, alkyl, alkanoyl, arylcarbonyl, heteroarylcarbonyl, carbamoyl, alkylsulfonyl, or arylsulfonyl; with the proviso that if R.sub.4 is a 7-alkyl group, it must have a tertiary carbon atom bonded to the ring;
- wherein the term "aryl" refers to phenyl and phenyl substituted with 1, 2 or 3 amino, alkylamino, dialkylamino, nitro, halogen, hydroxyl, trifluoromethyl, alkyl or 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, alkanoyloxy carbamoyl, or carboxyl groups;
- the term "heteroaryl" refers to pyridinyl, pyrrolyl, imidazolyl, furyl, thienyl, or thiazolyl;
- the term "nitrogen containing heteroaryl" refers to pyridinyl, pyrrolyl, imidazolyl and thiazolyl;
- the terms "alkyl" and "alkoxy" refer to groups having 1 to 10 carbon atoms;
- the terms "alkenyl" and "alkynyl" refer to groups having 2 to 10 carbon atoms;
- the term "alkanoyl" refers to groups having 2 to 11 carbon atoms; and
- the term "cycloalkyl" refers to groups having 3, 4 5, 6 or 7 carbon atoms.
- 2. A compound in accordance with claim 1 wherein R.sub.2 and R.sub.3 are each independently alkyl or cycloalkyl or R.sub.2 and R.sub.3 together with the nitrogen atom to which they are attached are pyrrolidinyl, piperidinyl or morpholinyl; and
- X.sub.3 and X.sub.4 are each independently hydrogen, alkyl, alkanoyl, arylcarbonyl, heteroarylcarbonyl or carbamoyl.
- 3. A compound in accordance with claim 1 wherein R and R.sub.1 are hydrogen.
- 4. A compound in accordance with claim 1 wherein R is hydrogen and R.sub.1 is alkyl or R and R.sub.1 are each alkyl.
- 5. A compound in accordance with claim 1 wherein R is hydrogen and R.sub.1 is alkenyl.
- 6. A compound in accordnce with claim 5 wherein R is hydrogen and R.sub.1 is vinyl.
- 7. A compound in accordance with claim 1 wherein R is hydrogen and R.sub.1 is alkynyl.
- 8. A compound in accordance with claim 1 wherein R is hydrogen and R.sub.1 is aryl.
- 9. A compound in accordance with claim 1 wherein R is hydrogen and R.sub.1 is heteroaryl.
- 10. A compound in accordance with claim 1 wherein R is hydrogen and R.sub.1 is cycloalkyl.
- 11. A compound in accordance with claim 1 wherein R and R.sub.1 together with the carbon atom to which they are attached are cycloalkyl.
- 12. A compound in accordance with claim 1 wherein at least one of R.sub.2 and R.sub.3 is hydrogen.
- 13. A compound in accordance with claim 1 wherein R.sub.2 and R.sub.3 are each alkyl.
- 14. A compound in accordance with claim 13 wherein R.sub.2 and R.sub.3 are each methyl.
- 15. A compound in accordance with claim 1 wherein R.sub.2 and R.sub.3 are each cycloalkyl.
- 16. A compound in accordance with claim 1 wherein R.sub.2 and R.sub.3 are each arylalkyl.
- 17. A compound in accordance with claim 1 wherein R.sub.2 and R.sub.3 together with the nitrogen atom to which they are attached are pyrrolidinyl, piperidinyl or morpholinyl.
- 18. A compound in accordance with claim 1 wherein R.sub.4 is hydrogen.
- 19. A compound in accordance with claim 1 wherein R.sub.4 is halogen or trifluoromethyl.
- 20. A compound in accordance with claim 19 wherein R.sub.4 is chlorine or trifluoromethyl and is located in the 7-position of the benzazepine nucleus.
- 21. A compound in accordance with claim 1 wherein R.sub.5 is alkoxy.
- 22. A compound in accordance with claim 1 wherein R.sub.5 is methoxy and is located in the 4-position of the phenyl ring to which it is attached.
- 23. A compound in accordance with claim 1 wherein n is 2.
- 24. A compound in accordance with claim 1 wherein n is 3.
- 25. The d-cis enantiomer of a compound of claim 1.
- 26. The compound in accordance with claim 1, (cis)-7-chloro-1-[2-(dimethylamino)ethyl]-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-3-methyl-2H-1-benzazepin-2-one or a pharmaceutically acceptable salt thereof.
- 27. The compound in accordance with claim 1, (cis)-7-chloro-1-[2-(dimethylamino)ethyl]-3-ethyl-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-2H-1-benzazepin-2-one or a pharmaceutically acceptable salt thereof.
- 28. The compound in accordance with claim 1, (cis)-7-chloro-1-[2-(dimethylamino)ethyl]-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-3-(2-propenyl)-2H-1-benzazepin-2-one or a pharmaceutically acceptable salt thereof.
- 29. The compound in accordance with claim 1, (cis)-1-[2-(dimethylamino)ethyl]-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-3-methyl-7-(trifluoromethyl)-2H-1-benzazepin-2-one or a pharmaceutically acceptable salt thereof.
- 30. The compound in accordance with claim 1, (cis)-1-[2-(dimethylamino)ethyl]-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-3-(2-propenyl)-7-trifluoromethyl)-2H-1-benzazepin-2-one or a pharmaceutically acceptable salt thereof.
- 31. The compound in accordance with claim 1, (cis)-1-[2-(dimethylamino)ethyl]-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-3-propyl-7-(trifluoromethyl)-2H-1-benzazepin-2-one or a pharmaceutically acceptable salt thereof.
- 32. The compound in accordance with claim 1, (cis)-1-[2-(dimethylamino)ethyl]-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-3-(2-propenyl)-6-(trifluoromethyl)-2H-1-benzazepin-2-one or a pharmaceutically acceptable salt thereof.
- 33. The compound in accordance with claim 1, (cis)-1-[2-(dimethylamino)ethyl]-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-3-propyl-6-(trifluoromethyl)-2H-1-benzazepin-2-one or a pharmaceutically acceptable salt thereof.
- 34. The compound in accordance with claim 25, (d-cis)-1-[2-(dimethylamino)ethyl]-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-3-(2-propenyl)-6-(trifluoromethyl)-2H-1-benzazepin-2-one or a pharmaceutically acceptable salt thereof.
- 35. The compound in accordance with claim 25, (d-cis)-1-[2-(dimethylamino)ethyl]-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-3-ethyl-6-(trifluoromethyl)-2H-1-benzazepin-2-one or a pharmaceutically acceptable salt thereof.
- 36. The compound in accordance with claim 25, (d-cis)-1-[2-(dimethylamino)ethyl]-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-3-methyl-6-(trifluoromethyl)-2H-1-benzazepin-2-one or a pharmaceutically acceptable salt thereof.
- 37. The compound in accordance with claim 1, (cis)-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-3-methyl-1-[2-[methyl(phenylmethyl)amino]ethyl-6-(trifluoromethyl)-2H-1-benzazepin-2-one or a pharmaceutically acceptable salt thereof.
- 38. The compound in accordance with claim 1, (cis)-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-3-methyl-1-[2-(methylamino)ethyl]-6-(trifluoromethyl)-2H-1-benzazepin-2-one or a pharmaceutically acceptable salt thereof.
- 39. The compound in accordance with claim 1, (cis)-1-[2-(diisopropylamino)ethyl]-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-3-methyl-6-trifluoromethyl)-2H-1-benzazepin-2-one or a pharmaceutically acceptable salt thereof.
- 40. The d-cis enantiomer of a compound having the formula ##STR22## wherein R and R.sub.1 are each hydrogen or alkyl, R is hydrogen and R.sub.1 is alkenyl, alkynyl, aryl, heteroaryl or cycloalkyl, or R and R.sub.1 together with the carbon atom to which they are attached are cycloalkyl;
- R.sub.4 and R.sub.5 are each independently hydrogen, halogen, alkyl, alkoxy, aryloxy, arylalkoxy, arylakyl, hydroxy, alkanoyloxy, ##STR23## difluoromethoxy, trifluoromethyl, --NX.sub.3 X.sub.4, --SO.sub.m alkyl, or --SO.sub.m aryl;
- m is 0, 1 or 2;
- X.sub.1 and X.sub.2 are each independently hydrogen, alkyl, aryl or heteroaryl, or X.sub.1 and X.sub.2 together with the nitrogen atom to which they are attached are a nitrogen containing heteroaryl;
- X.sub.3 and X.sub.4 are each independently hydrogen, alkyl, alkanoyl, arylcarbonyl, heteroarylcarbonyl, carbamoyl, alkylsulfonyl, or arylsulfonyl;
- wherein the term "aryl" refers to phenyl and phenyl substituted with 1, 2 or 3 amino, alkylamino, dialkylamino, nitro, halogen, hydroxyl, trifluoromethyl, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, alkanoyloxy, carbamoyl, or carboxyl groups;
- the term "heteroaryl" refers to pyridinyl, pyrrolyl, imidazolyl, furyl, thienyl, or thiazolyl;
- the term "nitrogen containing heteroaryl" refers to pyridinyl, pyrrolyl, imidazolyl and thiazolyl;
- the terms "alkyl" and "alkoxy" refer to groups having 1 to 10 carbon atoms;
- the terms "alkenyl" and "alkynyl" refer to groups having 2 to 10 carbon atoms;
- the term "alkanoyl" refers to groups having 2 to 11 carbon atoms; and
- the term "cycloalkyl" refers to groups having 3, 4, 5, 6 or 7 carbon atoms.
Parent Case Info
This application is a continuation-in-part of U.S. patent application Ser. No. 917,130, filed Oct. 9, 1986, and now abandoned which is a continuation-in-part of U.S. patent application Ser. No. 808,183, filed Dec. 12, 1985, and now abandoned.
US Referenced Citations (5)
Non-Patent Literature Citations (4)
Entry |
The Merck Index, ninth edition, 1976, p. 425, Abstract No. 31187, Diltiazam. |
Chem. Pharm. Bull., vol. 33, pp. 634-641, Hasiyama et al. |
J. Cardiovasc. Pharm., vol. 7, p. 152 (1985), Yabana et al. |
J. Cardiovasc. Pharm., vol. 9, p. 173 (1987), Schoemaker et al. |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
917130 |
Oct 1986 |
|
Parent |
808183 |
Dec 1985 |
|